Sanofi Licenses Biomunex Pharmaceuticals' BiXAb Technology to Develop Bi- and Multi-Specific Antibodies
Shots:
- Biomunex to receive upfronts and milestones from Sanofi. Sanofi to get rights to access Biomunex’s BiXAb technology for the development of bi- and multi-specific antibody therapies and will also be responsible for its research and global commercialization
- The focus of the agreement is to utilize Biomunex’s platform to develop immunotherapies for multiple solid tumors including head-and-neck- gastric and pancreatic cancers
- Biomunex’ Plug-and-Play BiXAb is biospecific antibody platform involved in the development of bi- and multi-specific antibodies in multiple therapeutic areas including immune-mediated inflammatory and infectious diseases
Ref: Biomunex Phatmaceuticals| Image: Mab Design
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
